Weiguang Zeng

Dr. Weiguang Zeng

Department of Microbiology & Immunology, Peter Doherty Institute for Infection & Immunity, University of Melbourne, Parkville 3010, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2010 in Amino Acids
Verified
Journal Article
Closed access
PDF file
WZWeiguang Zeng
Weiguang Zeng
EEEmily Eriksson
Emily Eriksson
BCBrendon Chua
Brendon Chua
LGLara Grollo
Lara Grollo
DJDavid Charles Jackson
David Charles Jackson

8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
GDGeorgia Deliyannis
Georgia Deliyannis
CWChinn Yi Wong
Chinn Yi Wong
HMHayley A. McQuilten
Hayley A. McQuilten
ABAnnabell Bachem
Annabell Bachem
MCMichele Clarke
Michele Clarke
BCBrendon Y. Chua
Brendon Y. Chua
The impact of respiratory virus infections on global health is felt not just during a pandemic, but endemic seasonal infections pose an equal and ongoing risk of severe disease. Moreover, vaccines and antiviral drugs are not always effective or available for many respiratory viruses. We investigated how induction of effective and appropriate antigen-independent innate immunity in the upper airways can prevent the spread of respiratory virus infection to the vulnerable lower airways. Activation of TLR2, when restricted to the nasal turbinates, resulted in prompt induction of innate immune–driven antiviral responses through action of cytokines, chemokines, and cellular activity in the upper but not the lower airways. We have defined how nasal epithelial cells and recruitment of macrophages work in concert and play pivotal roles to limit progression of influenza virus to the lungs and sustain protection for up to 7 days. These results reveal underlying mechanisms of how control of viral infection in the upper airways can occur and support the implementation of strategies that can activate TLR2 in nasal passages to provide rapid protection, especially for at-risk populations, against severe respiratory infection when vaccines and antiviral drugs are not always effective or available.

1 July 2015 in Vaccine
Verified
Journal Article
Closed access
WZWeiguang Zeng
Weiguang Zeng
ATAmabel C.L. Tan
Amabel C.L. Tan
KHKylie Horrocks
Kylie Horrocks
DJDavid Charles Jackson
David Charles Jackson

7 April 2016 in Scientific Reports
Verified
Journal Article
Open access
PRPradeep K Rai
Pradeep K Rai
SCSathi Babu Chodisetti
Sathi Babu Chodisetti
SNSajid Nadeem
Sajid Nadeem
SMSudeep Kumar Maurya
Sudeep Kumar Maurya
UGUthaman Gowthaman
Uthaman Gowthaman
DADr. Javed Naim Agrewala
Dr. Javed Naim Agrewala
Regardless of the fact that potent drug-regimen is currently available, tuberculosis continues to kill 1.5 million people annually. Tuberculosis patients are not only inflicted by the trauma of disease but they also suffer from the harmful side-effects, immune suppression and drug resistance instigated by prolonged therapy. It is an exigency to introduce radical changes in the existing drug-regime and discover safer and better therapeutic measures. Hence, we designed a novel therapeutic strategy by reinforcing the efficacy of drugs to kill Mtb by concurrently boosting host immunity by L91. L91 is chimera of promiscuous epitope of Acr1 antigen of Mtb and TLR-2 agonist Pam2Cys. The adjunct therapy using drugs and L91 (D-L91) significantly declined the bacterial load in Mtb infected animals. The mechanism involved was through enhancement of IFN-γ+TNF-α+ polyfunctional Th1 cells and IL-17A+IFN-γ+ Th17 cells, enduring memory CD4 T cells and downregulation of PD-1. The down-regulation of PD-1 prevents CD4 T cells from undergoing exhaustion and improves their function against Mtb. Importantly, the immune response observed in animals could be replicated using T cells of tuberculosis patients on drug therapy. In future, D-L91 therapy can invigorate drugs potency to treat tuberculosis patients and reduce the dose and duration of drug-regime.

1 January 2011 in Molecular Immunology
Verified
Journal Article
Closed access
WZWeiguang Zeng
Weiguang Zeng
EEEmily M. Eriksson
Emily M. Eriksson
ALAndrew Lew
Andrew Lew
DJDavid Charles Jackson
David Charles Jackson

6 October 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
PRPradeep K. Rai
Pradeep K. Rai
SCSathi Babu Chodisetti
Sathi Babu Chodisetti
WZWeiguang Zeng
Weiguang Zeng
SNSajid Nadeem
Sajid Nadeem
SMSudeep Kumar Maurya
Sudeep Kumar Maurya
DADr. Javed Naim Agrewala
Dr. Javed Naim Agrewala
The current BCG vaccine induces only short-term protection against Mycobacterium tuberculosis (Mtb), suggesting its failure to generate long-lasting memory T cells. Previously, we have demonstrated that a self-adjuvanting peptide of Mtb (L91), successfully generated enduring memory Th1 cells. Consequently, we investigated if L91 was able to recuperate BCG potency in perpetuating the generation of memory T cells and protection against Mtb infected mice. In the present study, we evaluated the potency of a self adjuvanting Mtb peptide vaccine L91 in invigorating BCG immune response against Mtb in mice. Female BALB/c mice were immunized with BCG. Later, they were boosted twice with L91 or an antigenically irrelevant lipidated influenza virus hemagglutinin peptide (LH). Further, PBMCs obtained from BCG vaccinated healthy subjects were cultured in vitro with L91. T cell responses were determined by surface markers and intracellular cytokine staining. Secretion of cytokines was estimated in the culture supernatants (SNs) by ELISA. Compared to the BCG-vaccinated controls, L91 booster significantly enhanced the percentage of memory Th1 cells and Th17 cells and reduced the mycobacterial burden in BCG primed and L91-boosted (BCG-L91) group, even after 229 days of BCG vaccination. Further, substantial augmentation in the central (CD44hiCD62LhiCD127hi) and effector memory (CD44hiCD62LloCD127lo) CD4 T cells was detected. Furthermore, greater frequency of polyfunctional Th1 cells (IFN-γ+TNF-α+) and Th17 cells (IFN-γ+IL-17A+) was observed. Importantly, BCG-L91 successfully prevented CD4 T cells from exhaustion by decreasing the expression of PD-1 and Tim-3. Additionally, augmentation in the frequency of Th1 cells, Th17 cells and memory CD4 T cells was observed in the PBMCs of the BCG-vaccinated healthy individuals following in vitro stimulation with L91. Our study demonstrated that L91 robustly reinvigorate BCG potency to invoke enduring protection against Mtb. This novel vaccination stratagem involving BCG-priming followed by L91-boosting can be a future prophylactic measure to control TB.